CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER 64170

ADMINISTRATIVE DOCUMENTS

ANDA APPROVAL SUMMARY

ANDA: 64-170

DRUG PRODUCT: Cefazolin for Injection USP (former title: Sterile Cefazolin Sodium USP)

FIRM: Fujisawa USA, Inc.

DOSAGE FORM: Sterile Powder (IM or IV)

STRENGTHS/CONFIGURATIONS: 10 g/100 mL vial; 20 g/100 mL vial (pharmacy bulk packages)

CGMP STATEMENT/EIR UPDATE STATUS: Signed cGMP certification provided on page 124 (12/12/95 submission). Acceptable EER dated 3/24/97.

BIO STUDY: Bio-study waiver request under CFR 320.22(b) was granted by the Division of Bioequivalence (2/19/97).

METHOD VALIDATION - (DESCRIPTION OF DOSAGE FORM SAME AS FIRM'S): The drug substance and drug product are both USP. The applicant is using a potency of the bulk drug and finished product. The firm's method was validated and shown to yield comparable results with the USP method.

STABILITY - (ARE CONTAINERS USED IN STUDY IDENTICAL TO THOSE IN CONTAINER SECTION?): The container/closure system used in the stability study was identical to that described in the container section.

LABELING: FPL found acceptable 2/23/98 by J.White

STERILIZATION VALIDATION (IF APPLICABLE): Application recommended for approval on the basis of sterility assurance (see Micro Review #2; 11/19/97).

SIZE OF BIO BATCH (FIRM'S SOURCE OF NDS OK?): The applicant's exhibit batches yielded and They were manufactured with active ingredient from Fujisawa Japan (ANDA 64-173; approved 9/97).

SIZE OF STABILITY BATCHES - (IF DIFFERENT FROM BIO BATCH, WERE THEY MANUFACTURED VIA THE SAME PROCESS?): Both exhibit batches were used in generating accelerated and room temperature stability data to support the 24 month expiry date. Data to support stability claims made in the package insert for the constituted product were also provided.

PROPOSED PRODUCTION BATCH - (MANUFACTURING PROCESS THE SAME AS BIO/STABILITY?): The proposed production batch size is vials ials
The manufacturing process described in the master production record is identical to that described in the exhibit batch record.

CHEMIST: Susan Rosencrance **DATE:** 2/23/98 2/26/9

TEAM LEADER: John Harrison **DATE:** 2/23/98 2/26/1998

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER 64170

CORRESPONDENCE

MINOR AMENDMENT

MAR 20 1997

AADA: [redacted]

64-170 [10 g and 20 g/vial pharmacy bulk package]

OFFICE OF GENERIC DRUGS, CDER, FDA
Document Control Room, Metro Park North II
7500 Standish Place, Room 150
Rockville, MD 20855-2773 ([redacted])

TO: APPLICANT: Fujisawa USA, INC. PHONE: (847) 317-8872
ATTN: Mr. Donald Baker FAX: (847) 317-[redacted] 1241

FROM: Mark Anderson
Jason A. Gross, Pharm.D., (301) 594-[redacted] 1841, PROJECT MANAGER

Dear Sir:

This facsimile is in reference to your abbreviated antibiotic applications dated December 12, 1995, submitted pursuant to Section 507 of the Federal Food, Drug, and Cosmetic Act, for Sterile

a.
b. Cefazolin Sodium USP (10 g & 20 g/vial pharmacy bulk package)

Reference is also made to your amendments dated October 8, 1996.
The application is deficient and, therefore not approvable under Section 507 of the Act for the reasons provided in the attachments (12 pages). This facsimile is to be regarded as an official FDA communication and unless requested, a hard copy will not be mailed.

The file on this application is now closed. You are required to take an action described under 21 CFR 314.120 which will either amend or withdraw the application. Your amendment should respond to all of the deficiencies listed. Facsimiles or partial replies will not be considered for review, nor will the review clock be reactivated until all deficiencies have been addressed. The response to this facsimile will be considered to represent a MINOR AMENDMENT and will be reviewed according to current OGD policies and procedures. The designation as a MINOR AMENDMENT should appear prominently in your cover letter. You have been/will be notified in a separate communication from our Division of Bioequivalence of any deficiencies identified during our review of your bioequivalence data. If you have substantial disagreement with our reasons for not approving this application, you may request an opportunity for a hearing. For further clarification or assistance please contact the Project Manager listed above.

SPECIAL INSTRUCTIONS: Pkg contains combined comments for chemistry (2 pgs), and separate comments for micro (1 pg each) and labeling (4 pages each)

38. **CHEMISTRY COMMENTS TO BE PROVIDED TO THE APPLICANT**

AADA: 64-170 APPLICANT: Fujisawa

DRUG PRODUCT: Sterile Cefazolin Sodium USP

The deficiencies presented represent Minor deficiencies.

A. Deficiencies:

1

B. In addition to responding to the deficiencies presented above, please note and acknowledge the following comment in your response:

2. Please submit 10 immediate containers from each batch for batch numbers R035-006 and R035-010 to:

Food and Drug Administration
Beltsville Research Facility
Attention: Valerie Flournoy (HFD-910)
8501 Muirkirk Road
Laurel, MD 20708 (Telephone: 301-827-8054)

A copy of the latest Certificate of Analysis should accompany the samples. The samples will be tested to verify the quality of the product.

Sincerely yours,

Frank O. Holcombe, Jr., Ph.D.
Director
Division of Chemistry II
Office of Generic Drugs
Center for Drug Evaluation and Research

000 00007

Microbiology Comments to be Provided to the Applicant

AADA/ANDA: 64-170 APPLICANT: Fujisawa USA, Inc

DRUG PRODUCT: Sterile Cefazolin Sodium USP

A. Microbiology Deficiencies:

B. In addition to responding to the deficiencies presented above, please note and acknowledge the following comments in your response:

1. Approval of this ANDA is dependent on approval of AADA 64-173 and

Please clearly identify your amendment to this facsimile as "RESPONSE TO MICROBIOLOGY DEFICIENCIES".

Sincerely yours,

Frank O. Holcombe, Jr., Ph.D.

Director
Division of Chemistry II
Office of Generic Drugs
Center for Drug Evaluation and Research

REVIEW OF PROFESSIONAL LABELING
DIVISION OF LABELING AND PROGRAM SUPPORT
LABELING REVIEW BRANCH

AADA Number: 64-170 Date of Submission: Feburary 12, 1996

Applicant's Name: Fujisawa USA, Inc.

Established Name: Sterile Cefazolin Sodium USP, 10 and 20 g Pharmacy Bulk Packages

Labeling Deficiencies:

A. CHEMISTRY DEFICIENCIES

B. LABELING DEFICIENCIES

1. CONTAINER (10 g and 20 g)

   a. Usual Dosage - 250 mg to 1 g every six to eight hours. See package insert.

   b. We encourage you to differentiate between your two product strengths by the use of boxing, contrasting colors, or some other means.

3. CARTON (1 X 10 vials) 10 g and 20 g

   See comments under CONTAINER.

4. INSERT

   a. DESCRIPTION

      i. ...for intramuscular and intravenous administration.

      ii. ...vials equivalent to 10 g or 20 g of cefazolin and are intended for intravenous infusion only.

   b. INDICATIONS AND USAGE

      i. Respiratory Tract infections, second paragraph - ...injectable penicillin G benzathine is ...

      ii. "Urinary Tract Infections" subsection heading should read "Genitourinary Tract Infections". In addition "Enterobacter should appear in italics.

iii. Skin and Skin Structure Infections - ...aureus (including penicillinase-producing strains) and group...

iv. Genital Infections - Delete this subsection.

v. Septicemia - ...aureus (penicillin-susceptible and...

vi. Endocarditis - aureus (penicillin-susceptible and...

vii. Perioperative Prophylaxis

1) Paragraph 1 - "...(e.g. vaginal hysterectomy, and cholecystectomy ...common-bile-duct stones)".

2) Paragraph 3 - "...procedure. For surgery in which the occurrence...".

3) Combine paragraphs 3 and 4.

c. CONTRAINDICATIONS

The text following the section heading should appear in lower case letters.

d. WARNINGS

i. Revise the fourth paragraph as follows:

Antibiotics, including cefazolin, should be administered cautiously to any patient who has demonstrated some form of allergy, particularly to drugs.

ii. Paragraph 6 - ..."antibiotic-associated-colitis". Cholestyramine...

iii. Add the following as the last subsection:

Usage in infants- Safety for use in premature and infants under 1 month of age has not been established.

e. PRECAUTIONS

i. General - Delete paragraphs 4 and 5.

ii. Drug interactions - Used concurrently, probenecid may decrease renal tubular secretion of cephalosporins resulting in...

iii. Drug/Laboratory Test Interactions

1) "false-positive" (add a hyphen)

iv. Pregnancy - ...studies have been performed in rats given doses of 500 mg or 1 g of cefazolin/kg and have revealed no harm to the fetus due to cefazolin...

v. Labor and Delivery - ...blood have been measured to be approximately one fourth to one...

vi. Delete the Pediatric Use subsection.

f. ADVERSE REACTIONS

i. Hepatic - Transient rise in AST(SGOT), ALT(SGPT), and alkaline...

ii. Gastrointestinal - "(See WARNINGS)"

g. DOSAGE AND ADMINISTRATION

i. Perioperative Prophylactic Use, item b - ...(e.g., 2 hours or longer)...

ii. Pediatric Dosage - Remove the subsection heading "Pediatric Dosage".

iii. Delete the terminal zero's form the kg and volume needed columns in the two tables.

iv. Usage in Neonates

1) Remove the subsection heading.

2) Since safety for use in premature infants and in infants under 1 month of age has not been established the ...

v. Relocate the Intravenous Administration subsection so that it follows immediately table 5.

vi. Intermittent intravenous infusion

1) Revise as follows: "...(...chloride injection), Lactated Ringer's Injection, 5% or 10% Invert Sugar in Sterile Water for Injection, Ringer's Injection...

vii. Stability

1) "Stability" is a subsection heading and should appear consistent with your format for other subsection headings.

2) Secondary Diluents - Solutions of Cefazolin for infusion in 10% Dextrose Injection, 5% Dextrose in Lactated Ringer's Injection, 5% Dextrose and 0.9% Sodium Chloride Injection (also may be used with 5% Dextrose and 0.45% or 0.2% Sodium Chloride Injection), Lactated Ringer's Injection, 5% or 10% Invert Sugar in Sterile water for Injection, Ringer's Injection...under refrigeration 2 to 8° C(36 to 46° F). (DO NOT FREEZE CEFAZOLIN DILUTED WITH THE ABOVE DILUENTS.)

3) Insert the following text:

NOTE: Administration of compounded admixtures should be as soon after preparation as is feasible.

4) Delete the chemical stability data for the pharmacy bulk package which implies storage for 10 days in a refrigerator or 24 hours at room temperature.

Please revise your labels and labeling, as instructed above, and submit final printed container labels and draft insert labeling.

Please note that we reserve the right to request further changes in your labels and/or labeling based upon changes in the approved labeling of the listed drug or upon further review of the application prior to approval.

To facilitate review of your next submission, and in accordance with 21 CFR 314.94(a)(8)(iv), please provide a side-by-side comparison of your proposed labeling with your last submission with all differences annotated and explained.

Jerry Phillips
Director
Division of Labeling and Program Support
Office of Generic Drugs
Center for Drug Evaluation and Research

FUJISAWA USA, Inc.
Parkway North Center, Three Parkway North
Deerfield, Illinois 60015-2548
Tel. (847) 317-8800 • Telefax (847) 317-7286

Fujisawa

TPL
NDA ORIG AMENDMENT
AM

February 6, 1998

Mr. Douglas Sporn, Director
Office of Generic Drugs
Food and Drug Administration
Center for Drug Evaluation and Research, HFD-600
Metro Park North II
7500 Standish Place, Rm. 150
Rockville, Maryland 20855-2773

RE: ANDA 64-170
Cefazolin for Injection, USP
10 g/100 mL Vial
20 g/100 mL Vial
Pharmacy Bulk Package
Manufacturing Site: Grand Island, NY

MINOR TELEPHONE AMENDMENT

Dear Mr. Sporn:

Reference is made to our Abbreviated New Drug Application submitted December 12, 1995. References are also made to the October 3,1997 amendment, January 6, 1998 FDA teleconference regarding Microbiology comments and the attached January 8, 1998 minor "Telephone Amendment - Chemistry, Labeling". For ease of review, this submission contains a copy of the deficiency letter and provides responses for each comment in the order as delineated in the deficiency letter.

In compliance with 21 CFR §314.96(b), a true and complete copy of this minor "telephone amendment" is being provided to the Acting Director, Food and Drug Administration, Buffalo District, 599 Delaware, Buffalo, NY 14202.

Should you have any questions or require additional information concerning this application, please do not hesitate to contact the undersigned at **(847) 317-8679** or Donald E. Baker, J.D. at **(847) 317-8872**.

Sincerely,

Genny Cruz

Genny Cruz
Senior Regulatory Scientist

L:\WP60\SHARE\CEFAZ170.COV

RECEIVED
FEB
GENERIC DRUGS

Nadine 2.10-98

Fujisawa

E L E C T R O N I C M A I L M E S S A G E

nsitivity: COMPANY CONFIDENTIAL

Date: 20-Jan-1998 03:15pm EST
From: Susan Rosencrance
ROSENCRANCES
Dept: HFD-643 MPN2 279
Tel No: 301-827-5849 FAX 301-594-3839

(ANDERSONM)

O: Mark Anderson

ubject:

y suggestion is we tell the firm they must address the deficiencies
ised in the fax which pertain to their Technical Report PS
7-PR/F-018. The Study Protocol: PS98-SP/F-001 looks OK other than the
uestion concerning the
nalysis.

usan

I called firm on 1/22/97 and relayed that proposals were Acceptable to microbiologist and Chemist but to address issues raised in our faxed comments

Mark Anderson

AADA 64-170

Fujisawa USA, Inc.
Attention: Donald E. Baker
3 Parkway North, 3rd Floor
Deerfield, IL 60015-2548

NOV 4 1996

Dear Sir:

We acknowledge the receipt of your abbreviated antibiotic application submitted pursuant to Section 507 of the Federal Food, Drug and Cosmetic Act.

Reference is also made to our "Refuse to File" letters dated February 2, and May 3, 1996, and your amendments dated February 12, and October 8, 1996.

NAME OF DRUG: Sterile Cefazolin Sodium USP, (Pharmacy Bulk Package) 10 g/vial and 20 g/vial

DATE OF APPLICATION: December 12, 1995

DATE OF RECEIPT: December 13, 1995

DATE ACCEPTABLE FOR FILING: October 9, 1996

We will correspond with you further after we have had the opportunity to review your application.

Please be advised that during the AADA approval process, samples of the active and inactive ingredients, and the AADA exhibit batch(es) (which should be the same as the biobatch if a bioequivalence study was conducted) may be collected by the FDA district office staff and tested by FDA district or headquarters laboratory staff. Drug substance standards and manufacturer's documentation of the impurity profile should be made available. In addition, batch records, certificates of analysis and specifications and tests for the drug substance, drug product and inactive ingredients may be collected.

The subject product of an AADA must conform to the current official compendial monograph requirements and be compatible with the test and assay methods described in that monograph. You must submit adequate documentation and laboratory data in your AADA that prove that any non-official alternate procedures that you choose to use for the analytical control (release) of your product are equivalent to the official compendial procedures. If this information is not submitted, the review of the application will be delayed.

Please identify any communications concerning this application with the number shown above.

Should you have questions concerning this application contact:

Robert L. West
Project Manager
(301) 594-0360

Sincerely yours,

11/4/96

Jerry Phillips
Director
Division of Labeling and Program Support
Office of Generic Drugs
Center for Drug Evaluation and Research

AADA 64-170
cc: DUP/Jacket
Division File
HFD-82
Field Copy
HFD-600/Reading File
HFD-615/MBennett
HFD-473/Antimicrobial Drugs Branch
Endorsements: HFD-615/PRickman, Chief, RSP _____date 11/1/96
HFD-615/HGreenber, CSO _____date 11/4/96
HFD-643/JHarrison, Supv. _____date
File x:\NEW\FIRMSAM\FUJISAWA\LTRS&REV\64170ack.F
F/T by HRW 10-29-96
AADA Acknowledgement Letter!

ARCHIVAL

Fujisawa USA, Inc.
Parkway North Center, Three Parkway North
Deerfield, Illinois 60015-2548
Tel. (847) 317-8872 • Telefax (847) 317-72[illegible]

Fujisawa

Donald E. Baker, J.D.
Director
Regulatory Affairs

10122496

AC

October 8, 1996

RECEIVED
OCT 09 1996
GENERIC DRUGS

Mr. Douglas Sporn,
Director
Office of Generic Drugs
Center for Drug Evaluation and Research
Metro Park North II, HFD-600 Room 150
Food and Drug Administration
7500 Standish Place
Rockville, MD. 20855

RE: AADA 64-170
Sterile Cefazolin Sodium, USP
(10 g/vial and 20 g/vial [Pharmacy Bulk Package])

AMENDMENT

Dear Mr. Sporn:

Reference is made to the letter dated May 3, 1996, regarding our abbreviated antibiotic application (AADA) submitted to FDA on December 12, 1995 for the above referenced Sterile Cefazolin Sodium, USP drug product. (Attachment I.)

Please be advised that Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan; through its Agent, Dr. A. E. DeWald, has been notified by the FDA on September 13, 1996, that Fujisawa's antibiotic application AADA 64-173 for Sterile Cefazolin Sodium, USP, (Bulk) has been officially accepted for filing. (Attachment II.)

We hope that the above information is sufficient to resolve the matter. Should you require any additional information please do not hesitate to call the undersigned at **(847) 317-8872** or Jerry D. Johnson, Ph.D. at **(847) 371-8898.**

(317)

Sincerely,

Donald E. Baker
Director, Regulatory Affairs

Attachment

baker\ltr\ds1079.1

AADA 64-170

Fujisawa USA, Inc.
Attention: Jerry D. Johnson, Ph.D.
3 Parkway North, 3rd Floor
Deerfield, IL 60015-2548

MAY 3 1996

Dear Sir:

Please refer to your abbreviated antibiotic application (AADA) dated December 13, 1995, submitted under Section 507 of the Federal Food, Drug and Cosmetic Act for Cefazolin Sodium USP, (Pharmacy Bulk Package) 10 g/vial and 20 g/vial.

Reference is also made to our "Refuse to File" letter dated February 2, 1996, and your amendment dated March 4, 1996.

We have given your application a preliminary review, and we find that it is not sufficiently complete to merit a critical technical review.

We are refusing to file this AADA under 21 CFR 314.101(d)(3) for the following reasons:

> This application will not be accepted for filing until the bulk antibiotic application that you reference is filed. It is an inefficient use of OGD's resources to review this application until the corresponding bulk antibiotic application is filed.

Thus, it will not be filed as an abbreviated antibiotic application within the meaning of Section 507 of the Act.

Within 30 days of the date of this letter you may amend your application to include the above information or request in writing an informal conference about our refusal to file the application. To file this application over FDA's protest, you must avail yourself of this informal conference.

If after the informal conference, you still do not agree with our conclusion, you may make a written request to file the application over protest, as authorized by 21 CFR 314.101(a)(3). If you do so, the application shall be filed over protest under 21 CFR 314.101(a)(2). The filing date will be 60 days after the date you requested the informal conference. If you have any questions please call:

Harvey Greenberg
Consumer Safety Officer
(301) 594-0315

Sincerely yours,

5/3/96

Jerry Phillips
Acting Director
Division of Labeling and Program Support
Office of Generic Drugs
Center for Drug Evaluation and Research

AADA 64-170
cc: DUP/Jacket
Division File
HFD-82
File Copy
HFD-600/Reading File
HFD-615/MBennett

Endorsement: HFD-615/PRickman, Chief ___date
HFD-615/HGreenber, CSO, _date
HFD-643/JHarrison, Sup ___date 4/2/96
File x:\new\firmsam\Fujisawa\ltrs&rev\64170.rt2
F/T File hrw 4-29-96
AADA Refuse to File!

ARCHIVAL

Fujisawa USA, Inc.
Parkway North Center, Three Parkway North
Deerfield, Illinois 60015-2548
Tel. (847) 317-8872 • Telefax (847) 317-7286

Fujisawa

Donald E. Baker, J.D.
Director
Regulatory Affairs

called Firm - Lyn Heller 2/1/96

February 12, 1996

Mr. Jerry Phillips
Acting Director
Division of Labeling and Program Support
Office of Generic Drugs
Center for Drug Evaluation and Research
Metro Park North II, HFD-600 Room 150
Food and Drug Administration
7500 Standish Place
Rockville, MD 20855

RECEIVED
NEW CORRESP
NC Ref
FEB 13 1996
GENERIC DRUGS

Re:

AADA 64-170
(10 g/vial and 20g/vial [Pharmacy Bulk Package])

AMENDMENT

Dear Mr. Phillips:

Reference is made to your letters provided in **Attachment 1**, dated February 1 and 2, 1996, regarding our abbreviated antibiotic applications (AADAs) submitted to FDA on December 12, 1995 for the above referenced Sterile Cefazolin Sodium, USP drug products .

Reference is also made to telephone conversations with Mr. Harvey Greenberg, (CSO) on February 6 and 7, 1996, regarding clarification pertaining to our reference to Drug Master File) to support the review of our AADAs 64-170.

On September 26, 1989, Dr. A. E. DeWald, the U.S. Agent for Fujisawa Pharmaceutical Co., Ltd., Japan, submitted to Mr. John Harrison, Chief of the Antibiotic Drug Review Branch, Division of Generic Drugs, a document entitled "Drug Master File for Chemistry, Manufacturing and Controls of Sterile Cefazolin Sodium, USP (Bulk)". The document submitted was equivalent to a bulk antibiotic application, since it contained all the information required for review and approval of bulk antibiotic applications.

On November 17, 1989, Lyphomed (F-USA) submitted a supplemental application to its AADA

To support the review of the supplemental application , Fujisawa-Japan provided written authorization to FDA to refer to the Fujisawa Pharmaceutical Co., Ltd., Japan Drug Master File for Cefazolin Sodium, USP. However, at that time, an application number was not yet assigned by FDA to the bulk antibiotic Drug Master File document.

After the Division of Generic Drugs completed the review of the supplemental application and supporting data referenced in Fujisawa-Japan's bulk antibiotic Drug Master File document, the FDA issued an approval letter on February 27, 1990, fo

For the above reason, we respectfully request that our pending and 64-170 for Sterile Cefazolin Sodium, USP nd pharmacy bulk package respectively) be filed as abbreviated antibiotic applications within the meaning of Section 507 of the Act.

We hope that the above information is sufficient to resolve the matter. We are also willing to meet with the agency to discuss this matter further, should you so desire. Should you require any additional information, please do not hesitate to call the undersigned at (847) 317-8872,

Sincerely,

Donald E. Baker, J.D.
Director, Regulatory Affairs

cc: Mr. Harvey Greenberg, Consumer Safety Officer

AADA 64-170

Fujisawa USA, Inc.
Attention: Jerry D.Johnson, Ph.D.
3 Parkway North, 3rd Floor
Deerfield, IL 60015-2548

FEB 2 1996

Dear Sir:

Please refer to your abbreviated antibiotic application (AADA) dated December 13, 1995, submitted under Section 507 of the Federal Food, Drug and Cosmetic Act for Sterile Cefazolin Sodium USP, (Pharmacy Bulk Package) 10 g/vial and 20 g/vial.

We have given your application a preliminary review, and we find that it is not sufficiently complete to merit a critical technical review.

We are refusing to file this AADA under 21 CFR 314.101(d)(3) for the following reasons:

> We acknowledge your reference to However, our records indicate that a bulk antibiotic application has not been submitted to support the review of your application [21 CFR 433.1(b)(3)]. In addition, we refer you to the Office of Generic Drugs, Policy and Procedure Guide #27-90.

Thus, it will not be filed as an abbreviated antibiotic application within the meaning of Section 507 of the Act.

Within 30 days of the date of this letter you may amend your application to include the above information or request in writing an informal conference about our refusal to file the application. To file this application over FDA's protest, you must avail yourself of this informal conference.

If after the informal conference, you still do not agree with our conclusion, you may make a written request to file the application over protest, as authorized by 21 CFR 314.101(c). If you do so, the application shall be filed over protest under 21 CFR 314.101(b). The filing date will be 60 days after the date you requested the informal conference. If you have any questions please call:

Harvey Greenberg
Consumer Safety Officer
(301) 594-0315

Sincerely yours,

2/2/96

Jerry Phillips
Acting Director
Division of Labeling and Program Support
Office of Generic Drugs
Center for Drug Evaluation and Research

AADA 64-170
cc: DUP/Jacket
Division File
HFD-82
File Copy
HFD-600/Reading File
HFD-615/MBennett
Endorsement: HFD-615/PRickman, Chief, RS 1-24-96 date
HFD-615/HGreenbeg,CSO 1/24/96 date
HFD-643/JHarrison, SL date 2/1/96
File x:\new\firmsam\fijisaw\ltrs&rev\64170rtf.f
F/T bcw 1-23-96
AADA Refuse to File!

Fujisawa USA, Inc.
Parkway North Center, Three Parkway North
Deerfield, Illinois 60015-2548
Tel. (708) 317-8872 • Telefax (708) 317-7286

Fujisawa

Donald E. Baker
Director, Regulatory Affairs

December 12, 1995

Charles Ganley, M.D., Acting Director
Office of Generic Drugs
Metro Park North II, HFD-600, Room 150
Center for Drug Evaluation and Research
Food and Drug Administration
7500 Standish Place
Rockville, MD 20855-2773

Re: Sterile Cefazolin Sodium, USP
10 g/vial and 20 g/vial
Pharmacy Bulk Package
Manufacting Site: Grand Island, N. Y.
Number of Volumes: Two Volumes

Dear Dr. Ganley:

This application is being submitted, in duplicate, as an Abbreviated Antibiotic Drug Application in accordance with Title I, Sec. 101. Section 505(j) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. 355) to seek marketing clearance for Sterile Cefazolin Sodium, USP. Enclosed, for your conveniences, are three copies of the analytical methods and validation section for the drug substance and finished dosage form.

Fujisawa USA, Inc. will manufacture this product in the manufacturing facilities located at 3159 Staley Road, Grand Island, N.Y. 14072. This application contains all the information required describing the manufacturing and control of Sterile Cefazolin Sodium, USP (10 g/vial and 20 g/vial) using Applicable general procedural approaches/data may be cross-referenced to Fujisawa USA, Inc., In addition, this application contains a request for the waiver of in vivo bioequivalence studies.

This application has been formatted according to the information in Office of **Generic Drugs Policy and Procedure Guide #30-91, April 10, 1991.**

An archival and review copy of this submission are provided for your review. Furthermore, a field copy has been sent to the FDA Buffalo District Office in accordance with 21 CFR §314.94(d)(5). We certify that the field copy is a true copy of the Abbreviated New Drug Application herewith submitted.

Additionally, please note that since the developmental stability lots (10%) for the single dose application and pharmacy bulk package application were filled in sequence during the same time period, some of the documents, such as, batch records, validation reports contain cross references between the two drug product applications. Please be adivsed that the single dose application is being submitted to the FDA at the same time as the pharmacy bulk package application.

Should you have any questions or require additional information concerning this application, please do not hesitate to contact the undersigned at **(708) 317-8872** or Deepak Naik at **(708) 317-1088.**

Sincerely,

Donald E. Baker
Director,
Regulatory Affairs

FUJISAWA USA, Inc.
Parkway North Center, Three Parkway North
Deerfield, Illinois 60015-2548
Tel. (847) 317-8800 • Telefax (847) 317-7286

Fujisawa

October 3, 1997

Mr. Douglas Sporn, Director
Office of Generic Drugs
Food and Drug Administration
Center for Drug Evaluation and Research, HFD-600
Metro Park North II
7500 Standish Place, Rm. 150
Rockville, Maryland 20855-2773

ORIG AMENDMENT

RE: AADA 64-170
Sterile Cefazolin Sodium, USP
10 mg/100 mL Vial
20 mg/100 mL Vial
Pharmacy Bulk Package
Manufacturing Site: Grand Island, NY

MINOR AMENDMENT

Dear Mr. Sporn:

Reference is made to our Abbreviated Antibiotic Drug Application submitted December 12, 1995. Reference is also made to the attached not approvable letter dated March 20, 1997 which details chemistry, labeling and microbiology deficiencies. For ease of review, this submission contains a copy of the deficiency letter and provides responses for each comment in the order as delineated in the deficiency letter.

In compliance with 21 CFR §314.96(b), a true and complete copy of this minor amendment is being provided to the Acting Director, Food and Drug Administration, Buffalo District, 599 Delaware, Buffalo, NY 14202.

Should you have any questions or require additional information concerning this application, please do not hesitate to contact the undersigned at **(847) 317-8679** or Donald E. Baker, J.D. at **(847) 317-8872**.

Sincerely,

Genny Cruz
Senior Regulatory Scientist

RECEIVED
OCT 06 1997
GENERIC DRUGS